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above treatments and with the following endpoints: Sustained Virological Response 
(SVR), discontinuation of all medications (overall/due to Adverse Events (AE)), 
and incidence of anemia, rash (all grades) and pruritus-common adverse events 
of cHCV treatment. A Bayesian NMA was performed for all endpoints, assuming 
fixed study effects. Unpublished SMV studies meeting the inclusion criteria were 
obtained. Results: Three studies met the inclusion criteria: 2 phase III RCTs (SMV 
n= 183; TVR n= 189), and 1 SMV phase IIb RCT (n= 92). Baseline characteristics were 
generally comparable for all studies. SMV shows a higher odds ratio (OR) of achiev-
ing SVR versus TVR (OR 1.68 (0.66-4.26)). SMV shows a lower OR of discontinuation: 
overall 0.35 (0.12-1.00) and due to AEs 0.87 (0.23-3.34) versus TVR. SMV shows a lower 
OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.42 (0.17-0.99) but a higher OR 
of experiencing pruritus 1.26 (0.46-3.47) versus TVR. The main limitation of this 
study is the small number of trials included in the analysis. ConClusions: In this 
indirect comparison, SMV, in combination with PegIFN/RBV, showed a favourable 
risk-benefit profile compared to TVR with PegIFN/RBV in Japanese treatment-naïve 
Hepatitis C infected patients.
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objeCtives: Two meta-analyses (York Health Economics Consortium [YHEC]; 
Cochrane) reported the beneficial effects of probiotics (live microorganisms which 
when administered in adequate amount confer a health benefit on the host). They 
demonstrated efficacy at reducing the duration and number of upper respiratory 
tract infections (URTI) and antibiotics use. The purchase of probiotics by consumers 
is likely to have positive externalities to the national health system and society. The 
aim of this analysis was to estimate the public health consequences of probiotics 
consumption, in France. Methods: A 1/1,000 virtual age and gender standardized 
population was generated using a Markov model (TreeAge 2009). URTI risk factors 
were age, active/passive smoking, living in the community. Influenza like illness (ILI) 
and flu daily incidence rates came from Sentinelles, a practitioner network aimed 
at identifying flu outbreak. Epidemiologic data were used to differentiate cold, ILI 
and flu. One-day cycles were used over the 2011-2012 flu season. Probiotics effects 
came from two meta-analyses. Outcomes included numbers of URTIs days and 
episodes, antibiotics courses and sick leave days avoided with probiotics. Results: 
According to YHEC data, probiotics reduced URTI episodes (average 7 days) by -0.77 
days [-1.5;-0.04]. Extrapolating these results to the French population, probiotics 
would save 2.85 million URTI-days, the number of antibiotic courses would drop 
from 1,004,000 to 674,000 (difference about -330,000) and the number of sick leave 
days avoided in adults would be 653,000. According to Cochrane data, probiotics 
would reduce the probability to have an URTI episode by 0.58 [0.36;0.92] and anti-
biotic prescription by 0.67 [0.45;0.98]. The probiotic impact would become larger in 
terms of URTI-days avoided (-7.1 million), antibiotic courses (-509,000) and workdays 
lost (-1.2 million). ConClusions: The probiotics public health impact on URTI is 
significant at a national level even though this analysis was restricted to the 1% of 
patients visiting a practitioner.
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objeCtives: To predict the future incidence of chronic hepatitis C in Russia and assess 
potential impact of the available antiviral therapies (pegylated interferon a-2a/a-2b 
or standard interferon a-2b combined with ribavirin) on long-term morbidity and 
mortality rates in the population of newly diagnosed Russian patients with chronic 
hepatitis C. Methods: Based on the national epidemiologic data and published natu-
ral history studies, the prognostic Markov model was developed. Depending on the 
results of antiviral therapy, patients’ flows over 25-year time frame were simulated. 
End points of interests included: the incidence of compensated and decompensated 
cirrhosis, hepatocellular carcinoma and cumulative time that patients will spend in 
each state, the number of patients, who will require liver transplantation, and HCV-
related mortality rates. Results: During years 2013-2017 about 276,000 new cases 
of chronic hepatitis C will be diagnosed in Russia. After 25 years since being diag-
nosed 130, 189 and 227 of 1,000 patients received pegylated interferon a-2a, pegylated 
interferon a-2b and standard interferon a-2b, respectively, will develop compensated 
cirrhosis. The cumulative time that patients will spend in compensated cirrhosis state 
will be 848, 1,218 and 1,482 patient-years, respectively. During the established time 
frame, there will be expected 25, 36 and 43 cases of hepatocellular carcinoma and 35, 
51 and 62 HCV-related deaths. 28, 40 and 49 patients, respectively, will require liver 
transplantation. ConClusions: The findings from the present study provide the 
opportunity to plan volumes of medical care that will be required to Russian patients 
with chronic hepatitis C during 25 years since disease was first diagnosed. The treat-
ment with pegylated interferon alfa-2a is considered the most preferable strategy 
due to considerably lower long-term morbidity and mortality rates as compared to 
pegylated interferon a-2b and standard interferon a-2b treatment.
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deaths due to DND. This study is limited by its ecological nature and more rigor-
ous epidemiologic research is needed to elucidate the association between LD 
and DND.
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objeCtives: High pill burden has been associated with poor adherence to HAART 
and adverse clinical outcomes. This study evaluated the impact of HAART as a 
single-tablet regimen (STR) and multiple-tablet regimen (MTR) on outcomes in 
HIV patients within the Veteran’s Affairs (VA) system. Methods: A retrospective, 
cohort study assessed patient VA dispensation data for HIV medications during 
the study enrollment period (7/1/2006 to 9/30/2011). Patients were assigned to the 
following cohorts: STR if they received a HAART regimen of a single tablet/day or 
MTR if they received a regimen of ≥ 2 tablets/day and no single tablet/day regimen 
during the enrollment period. Patients were followed from the index date (start 
of HAART regimen) until the earliest of treatment discontinuation, end of study 
period, or last date of health care-related activity (eg, VA benefits file or death). 
Hospitalization and adherence (medication possession ratio [MPR] ≥ 95%) were 
evaluated. Multivariate cohort differences in outcomes were controlled for using 
Cox-proportional hazard and logistic models; covariates were measured during 
a 6-month baseline period. Results: In all, 15,602 patients (STR, n= 6,191; MTR, 
n= 9,411) met study criteria; average age of the study sample was 52 years. Both 
cohorts had similar CD4 counts (mean [SD]: 432.2 [282.8] vs 419.3 [280.9]; P= 0.287) 
but significantly fewer patients receiving STR vs MTR had an undetectable viral load 
at baseline (42% vs 46%, P< 0.001). During follow-up, significantly more STR patients 
were adherent compared to MTR patients (75% vs 55.7%, P< 0.001). STR patients were 
also significantly less likely to experience hospitalization compared to MTR patients 
(26.8% vs 31.3%, P< 0.001). After controlling for baseline covariates, STR patients 
had twice the odds of being adherent (OR: 1.98, P< 0.001) and 31% lower hazard of 
experiencing hospitalization during follow-up (HR: 0.69, P< 0.001). ConClusions: 
Treatment with STR compared to MTR improves adherence rates and decreases 
hospitalizations in patients with HIV/AIDS.
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objeCtives: Sofosbuvir (SOF) is a nucleotide polymerase inhibitor with excellent 
clinical efficacy in combination with ribavirin (RBV) for 12 weeks for patients who 
are chronically infected with hepatitis C virus (HCV) genotype 2. A decision-analytic 
Markov model evaluated the health outcomes of SOF+RBV compared with current 
treatment options for patients who are previously untreated, had no response to 
prior interferon treatment, or are unable to take interferon. Methods: The analysis 
modeled 3 cohorts of chronic HCV genotype 2 patients with an average age of 50 
and 25% with cirrhosis at the start of treatment followed-up to 100 years of age from 
a US third-party payer perspective. SOF+RBV for 12 weeks was compared with 1) 
pegylated interferon (PegIFN)+RBV for 24 weeks in the treatment-naïve patients; 
2) PegIFN+RBV for 48 weeks in the treatment-experienced; and 3) no treatment in 
those unable to take interferon. Sustained virologic response (SVR) and adverse 
event rates were based on phase III clinical trials. Transition probability, utility, 
and cost estimates (in 2013 US dollars) were based on a literature review, public 
sources, and consensus by a panel of 4 hepatologists. Results: In the treatment-
naïve cohort, the SOF+RBV regimen resulted in an 83% decrease in the cases of 
liver disease complications including hepatocellular carcinoma, decompensated 
cirrhosis, liver transplant, and HCV-related death compared with PegIFN+RBV. The 
reduction of the listed liver disease sequelae was 59% in the treatment-experienced 
vs. PegIFN+RBV and 93% in the interferon-unable cohort vs. no treatment. The num-
ber needed to treat (NNT) with SOF+RBV rather than PegIFN+RBV to achieve one 
additional SVR was 6 in the treatment-naïve and 4 in the treatment-experienced 
cohorts. ConClusions: SOF+RBV was projected to yield better health outcomes 
in genotype 2 patients compared to PegIFN+RBV, largely driven by superior efficacy, 
and the potential to cure those who are unable to take interferon-based therapies.
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objeCtives: Simeprevir (SMV) is an oral, once-daily potent protease inhibitor for 
the treatment of chronic Hepatitis C genotype-1 infection (cHCV). In phase IIb/III 
RCTs conducted in Japan, SMV, in combination with peginterferon-α and ribavirin 
(PegIFN/RBV), demonstrated potent efficacy in cHCV genotype 1-infected patients 
relative to PegIFN/RBV and was generally safe and well-tolerated. Telaprevir (TVR) 
in combination with PegIFN/RBV is licensed for the treatment of cHCV in Japan. 
In the absence of head-to-head comparisons of TVR and SMV, we undertook a 
network meta-analysis (NMA) to examine the relative efficacy and safety of SMV 
and TVR in combination with PegIFN/RBV in a Japanese population. Methods: A 
systematic review identified RCTs in Japanese treatment-naive patients with the 
